Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck
Open Access
- 1 January 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (1) , 119-122
- https://doi.org/10.1023/a:1008360323986
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.Journal of Clinical Oncology, 1998
- Docetaxel: an active drug for squamous cell carcinoma of the head and neck.Journal of Clinical Oncology, 1996
- Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublinesin vitroInvestigational New Drugs, 1994
- Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neckAnnals of Oncology, 1994
- The growth inhibiting effect of docetaxel (Taxotere®) in head and neck squamous cell carcinoma xenograftsCancer Letters, 1994
- Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell linesCancer Chemotherapy and Pharmacology, 1992
- Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neckBritish Journal of Cancer, 1986
- Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatinCancer, 1985